News

The study, a phase II double-blind, placebo controlled, multi-dose study in treatment-experience HIV patients, assessed SP01A’s safety and effect on viral load in HIV-1 positive individuals, with evidence

The transaction, which involved purchasing the outstanding 16.66% shares owned by Akzo Nobel’s main partner Chang Cheng Securities, means that the company now wholly owns its powder coatings

During the special protocol assessment (SPA) process, the FDA evaluates the adequacy of the proposed trial’s design to support the efficacy claims that will be part of the

The finding from the study suggests that two drugs in Micromet’s pipeline that target EpCAM may have utility in ovarian cancer. These drugs include the human antibody adecatumumab

Shingles is a frequently painful disease marked by a blistering rash. Caused by the reactivation of the virus that causes chickenpox, shingles can lead to severe complications including

Teva said that final approval of this ANDA is expected in April 2010 when patent protection for the brand product expires. The company last week said that the

A team at the University of California Los Angeles, led by Dr Michael Teitell, and collaborators at Harvard Medical School, The Rockefeller University and the National Institutes of

According to the company, hormone receptor-positive breast cancer affects two-thirds of patients with breast cancer and is typically considered 'lower-risk' due to successful treatment with hormonal therapies. However,

According to a source quoted by the company, Omnicef Capsules had US sales of approximately $232 million last year. Cefdinir is an extended-spectrum semisynthetic cephalosporin used to treat